

Sujeet Kumar
PhD (JNU), New Delhi

sujeet12in@gmail.com
kumarsujeet@gmail.com
Phone: +91-7033-778610

Total Experience: 23 Years

International Experience (Post PhD)

08 Years

- University of Oxford, Oxford, UK.
 - University of Saskatchewan, Saskatoon, Canada
 - University of Pennsylvania, Philadelphia, USA
 - University of Sciences, Philadelphia, USA
-

Profile Summary

A. Administrative Positions

1. **Director** – Institute of Innovation (PW), Pune.
January 2025 – till date.
2. **Principal** – Allied Health Sciences, DMIHER (Deemed University), Nagpur.
March 2024 - December 2024.
3. **University PhD Coordinator** – Amity University Maharashtra, Mumbai.
January 2021 - March 2024.
4. **Head- Centre for Proteomics & Drug Discovery (CPDD)** – Amity University Maharashtra, Mumbai. **October 2019 - March 2024.**
5. **Principal Investigator** (Extramural Research Grant) – ICMR, Gov. of India.
December 2019 - March 2023. (Total budget ~ 1.29 Crore)
6. Co-Principal Investigator (Extramural Research Grant) – ICMR, Gov. of India.
March 2023 - February 2026 (Ongoing). (Total budget ~ 51 Lacs)
7. Co-Principal Investigator (Extramural Research Grant) – ICMR, Gov. of India.
January 2026 (Commenced). (Total budget ~ 84 Lacs)

B. Academic Positions

1. **Professor** - Biotechnology & Bioinformatics.
DMIHER (Deemed University), Nagpur. **March 2024 - December 2024.**
2. **Associate Professor** - Biotechnology.
Amity University Maharashtra, Mumbai. **January 2021 - March 2024.**
3. **Assistant Professor** - Biotechnology.
Amity University Maharashtra, Mumbai. **July 2018 - December 2020.**

C. Research Profile Summary

1. **Extramural Funding:** ~ 2.6 Crore
2. **Total Publication:** 45
3. **Total Citations:** ~1400
4. **h-index:** 16
5. **i10- index:** 21

D. Funded Research Projects (awarded as Independent Investigator)

1. Extramural Research Grant awarded from **Indian Council of Medical Research**
Total Sanctioned Budget: 1.29 Crore. (Completed).

Project title: “Understanding the Information Bias in Targeting Drug Resistant in Cancer: The Peculiarity of BRAF Associated Mutants”.

2. Extramural Research Grant awarded from **Indian Council of Medical Research**
Total Sanctioned Budget: 51.36 Lacs. (Ongoing).

Project title: “Unraveling Human Adult Hippocampal Neurogenesis Using Immunohistochemical and Transcriptomic Methods: An Observational Study”.

3. Extramural Research Grant awarded from **Indian Council of Medical Research**
Total Budget: 83.87 Lacs. (Ongoing, To Commenced from Jan 2026).

Project title: “Age-Related Structural and Functional Alterations in Human Meningeal Lymphatics”.

E. Educational background

1. **Ph.D. :** Jawaharlal Nehru University (JNU) (2002 -2009).
(Selected through direct Interview, held for CSIR-JRF Qualified candidates)
2. **CSIR - JRF (cum UGC-NET):** Dec 2001 Examination
3. **M.Sc. :** Pondicherry (Central) University (2000 -2002).
(Selected through All India Biotechnology Entrance Exam, now known at GAT-B)

F. Summary – Salient Achievements

1. Held position within top 2% of the student’s – 10+2 Board Higher Secondary Examination (*erstwhile* then).
2. Selected for Postgraduate program through All India Entrance test and secured admission within top 10 ranking Central University (*erstwhile* then).
3. Qualified CSIR-UGC JRF & NET in the Final year of post-graduation.
4. PhD from Jawaharlal Nehru University (JNU), New Delhi (Consistently ranked within top 3 University of India).
5. First Professional Experience – AIIMS, New Delhi (Ranked No. 1 Medical Institute of India).
6. Shortlisted for Post Doc position at University of Oxford, UK (Consistently ranked within top 3, globally).
7. Post Doc from University of Saskatchewan, Canada (Ranked within top 400 - QS World University rankings).
8. Working experience at University of Pennsylvania, USA (an Ivy league Institute – top 7 ranking within USA & top 15 globally).

Dr. Sujeet Kumar PhD
(Biotechnology) JNU,
New Delhi

E-mail: kumarsujeet@gmail.com
sujeet12in@gmail.com

Telephone: +91-7033-778610 (M)
+91-9955-227799 (M)

<https://orcid.org/0000-0001-5427-8735>

www.linkedin.com/in/kumar-sujeet/

Current Designation & Affiliation
Director, PW Institute of Innovation,
Hadapsar, Pune
Maharashtra 411 013



A. Summary of Positions held – Academics & Research

S. No.	Institutional Affiliations	Tenure Duration
1.	Director PW Institute of Innovation, Pune, Maharashtra.	Jan 2025 – till date.
2.	Professor & Principal Datta Meghe Institute of Higher Education and Research (DMIHER), Deemed Univ., Nagpur, Maharashtra	Mar 2024 - Dec 2024.
3.	Associate Professor & Head Centre for Proteomics and Drug Discovery (CPDD), Amity University Maharashtra (AUM), Mumbai.	Jan 2021- Mar 2024.
4.	Assistant Professor (Sr. Grade) Amity Institute of Biotechnology, AUM, Mumbai.	Jul 2018- Dec 2020.
5.	Postdoctoral Fellow University of the Sciences, Philadelphia, PA, USA.	May 2016- Feb 2018.
6.	Postdoctoral Fellow University of Saskatchewan, Saskatoon, SK, Canada.	Apr 2010- Nov 2015.
7.	Research Associate (ICMR, Gov. of India) All India Institute of Medical Sciences (AIIMS), New Delhi.	Apr 2009- Mar 2010.
8.	Senior Research Fellow (DBT, Gov. of India) Jawaharlal Nehru university (JNU), New Delhi, India.	Aug 2007- Oct 2008.
9.	Senior Research Fellow (CSIR, Gov. of India) Jawaharlal Nehru university (JNU), New Delhi, India.	Aug 2004- July 2007.
10.	Junior Research Fellow (CSIR, Gov. of India) Jawaharlal Nehru university (JNU), New Delhi, India.	Aug 2002- July 2004.

B. University Education

2009	Ph.D (Biotechnology), Jawaharlal Nehru University (JNU), New Delhi, India. Thesis title: Effect of Polar Aprotic Solvents and the Structure and Dynamics of Proteins: A Case Study of Xylanase in DMSO Water Mixtures.
2002	M.Sc (Biotechnology; 1st Divison), Pondicherry University, Puducherry, India. Thesis title: Characterization of Exopolysaccharides Produced by <i>Pseudomonas</i> Pathovar Strains Using Infrared and Nuclear Magnetic Resonance.
2000	B.Sc (Chemistry, Honors; 1st Divison), Magadh University, Bodh Gaya, India.

C. Administrative Experience – Institute/University Level

1. **Director** – Institute of Innovation, Pune, Maharashtra (Jan 2025- till date).
2. **Principal** – School of Allied Health Sciences, Datta Meghe Institute of Higher Education and Research (DMIHER), Deemed Univ., Nagpur (Mar 2024 – Dec 2024).
3. **Member** (Jan 2021- Mar 2024) – **Academic Council**, Amity University Maharashtra.
4. **Member** (Jan 2021- Mar 2024) – **Board of University Teaching & Research (BUTR)**, Amity University Maharashtra.
5. **Head** (Jan 2021- Mar 2024) – **University PhD Program**, Amity University Maharashtra.
6. **Founder & Head** (Oct 2019- Mar 2024) – **Centre for Proteomics and Drug Discovery (CPDD)**, Amity University Maharashtra.

D. Extramural Research Projects (as an Independent Investigator)

1. **Principal Investigator** – “Understanding the Information Bias in Targeting Drug Resistant in Cancer: The Peculiarity of BRAF Associated Mutants”.

Funding : Indian Council of Medical Research (ICMR), Gov. of India.
Project ID : ISRM/12(44)/2019-2761
Duration : Dec 2019 - March 2023
Budget : Rs. 1,29,56,002/-

2. **Co-Principal Investigator** – “Unraveling Human Adult Hippocampal Neurogenesis Using Immunohistochemical and Transcriptomic Methods: An Observational Study”.

Funding : Indian Council of Medical Research (ICMR), Gov. of India.
Project ID : ICMR/IISRG//2021-10595
Duration : March 2023 - Feb 2026
Budget : Rs. 51,36,458/-

3. **Co-Principal Investigator** – “Age-Related Structural and Functional Alterations in Human Meningeal Lymphatics”.

Funding : Indian Council of Medical Research (ICMR), Gov. of India.
Project ID : DDR/01/IIRP-SG2025/03242
Duration : Jan 2026 - Dec 2028
Budget : Rs. 83,87,481/-

E. Extramural Research Projects (Others)

1. **Postdoctoral Fellow** (2016-2018) – “Unraveling Molecular Mechanisms and BRAF Activation to Improve Therapy in Melanoma” funded by The W.W. Smith Charitable Trust, Pennsylvania, USA.
2. **Postdoctoral Fellow** (2012-2015) – “Role of N-myristoyltransferase in Modulating Breast Cancer” funded by Canadian Breast Cancer Foundation (CBCF), Canada.
3. **Postdoctoral Fellow** (2011-2012) – “Development of a Blood Test for Colon Cancer” funded by Royal University Hospital (RUH) Foundation Research Fund, Saskatoon, Canada.
4. **Postdoctoral Fellow** (2011-2012) – “N-myristoyltransferase: A Novel Molecular Target for Cancer” funded by College of Medicine, University of Saskatchewan, Saskatoon, Canada.

5. **Postdoctoral Fellow** (2010-2011) – “***N*-myristoyltransferase: A Novel Molecular Target for Cancer**” funded by the Tri-Council Bridge Funding, University of Saskatchewan, Saskatoon, Canada.
6. **Research Associate** (2009-2010) – “**Cloning and Expression of Flagellin Gene of *Salmonella typhi*: An Immunodiagnostic Approach**” funded by Indian Council of Medical Research (ICMR), Ministry of Health and Family Welfare, Gov. of India.
7. **Senior Research Fellow** (2007-2008) – “**Metabolic Engineering of *E. coli* to Remove the Bottlenecks in Recombinant Protein Expression**” funded by Department of Biotechnology (DBT), Ministry of Science & Technology, Gov. of India.

F. Awards/ Scholarship/Outstanding achievements

1. **2015** “Saskatchewan Cancer Researcher Travel Award” by Canadian Cancer Society for poster presentation at ASBMB session at Experimental Biology, EB2015, Boston, USA.
2. **2014** “Conference Travel Fund” by College of Medicine, University of Saskatchewan, Saskatoon, for the poster presentation at “Chemical Biophysics Symposium (CBP-2014)”, University of Toronto, Toronto, Canada.
3. **2013** “Saskatchewan Cancer Researcher Travel Award” by Canadian Cancer Society. Oral presentation at International Conference on Biotechnology and Bioinformatics (ICBB-2014).
4. **2012** “Saskatchewan Cancer Researcher Travel Award” by Canadian Cancer Society for poster presentation at International Conference on Stem Cells and Cancer (ICSCC-2012).
5. **2011** “Saskatchewan Cancer Researcher Travel Award” by Canadian Cancer Society for poster presentation at American Association for Cancer Research meeting “New Horizons in Cancer Research: Biology to Prevention to Therapy” (December-2011).
6. **August 2004 - July 2007 Senior Research Fellow (SRF)**, Council of Scientific and Industrial Research (CSIR, India).
7. **August 2002 - July 2004 Junior Research Fellow (JRF)**, Council of Scientific and Industrial Research (CSIR, India).
8. **JRF cum NET (National Eligibility Test) in Life Sciences**, conducted by Council of Scientific and Industrial Research, CSIR (jointly with University Grants Commission, UGC)-December 2001 Examination.
9. **2000** Selection for M.Sc. Biotechnology program; “**All India Combined Biotechnology Entrance Examination-2000**” conducted by the Jawaharlal Nehru University (JNU), New Delhi, India.
10. **2000** Qualified for ‘**Officers Training Academy**’ (OTA); **Combined Defense Services Examination-2000**, conducted by the Union Public Service Commission (UPSC).
11. **2000** Qualified for ‘**Indian Military Academy**’ (IMA); **Combined Defense Services Examination-2000**, conducted by the Union Public Service Commission (UPSC).

G. Publications

1. Asthana S, Mohanty S, Kalra H, Karunanethi N, **Kumar S**, Agrawal N, Jha S (2025) Detergent induced structural perturbations in peanut agglutinin: Insights from spectroscopic and molecular dynamic simulation studies. *J. Biomol. Struct. Dyn.* **43**: 2852 -2863 [**Impact Factor: 2.7**]
2. Kumar A, Asghar A, Raza K, Narayan RK, Jha RK, Satyam A, Kumar G, Dwivedi P, Sahni C, Kumari C, Kulandhasamy M, Motwani R, Kaur G, Krishna H, **Kumar S**, Sesham K, Pandey SN, Parashar R, Kant K (2024) Shift in demographic involvement and clinical characteristics of COVID-19 from wild-type SARS-CoV-2 to the Delta variant in the Indian

- population: *in silico* analysis. *Interact J Med Res.* **13**: e44492. [Impact Factor: 1.9]
3. Singh P, Anand A, Rana S, Kumar A, Kumar S, Goel P, Gouda KC, Singh H (2024) Impact of COVID-19 Vaccination: A Global Perspective. *Front. Public Health.* **11**: 1272961. [Impact Factor: 3]
 4. Singh P, Bhaskar Y, Verma P, Rana S, Goel P, Kumar S, Gouda KC, Singh H (2023) Impact of comorbidity on patients with COVID-19 in India: A nationwide analysis. *Front. Public Health.* **10**: 1027312. [Impact Factor: 3]
 5. Kumar A, Asghar A, Singh HN, Faiq MA, Kumar S, Narayan RK, Kumar G, Dwivedi P, Sahni C, Jha RK, Kulandhasamy M, Prasoon P, Sesham K, Kant K, Pandey SN (2023) SARS-CoV-2 Omicron variant genomic sequences and their epidemiological correlates regarding the end of the pandemic: *in silico* analysis. *JMIR Bioinform Biotech.* **4**: e42700.
 6. Kumar A, Narayan RK, Kumar S, Pareek V, Kumari C, Jha RK, Prasoon P (2022) NRP1 and furin as putative mediators of SARS-CoV-2 entry into human brain cells. *Re:GEN Open* **2**: 103-109. [Impact Factor: 2.6]
 7. Kumar A, Narayan RK, Prasoon P, Jha RK, Kumar S, Kumari C, Pandey SN, Faiq MA (2022) COVID-19 vaccination may enhance hippocampal neurogenesis in adults. *Brain Behav Immun.* **107**: 87-89. [Impact Factor: 8.8]
 8. Lohia R, Goel P, Kaur J, Kumar S, Bajpai M, Singh H (2022) The COVID-19 experience: An analysis of epidemiological reflections from 170 million consecutive test results. *Front. Epidemiol.* **2**: 933820.
 9. Tiwari J, Tripathi N, Srivastava RS, Kumar S, Singh S, Jain S, Khattri A (2022) Low expression of TMPRSS2-a SARS-CoV-2 internalization protease-associates with basal subtype of head and neck squamous cell carcinoma. *Transl Oncol.* **22**: 101458. [Impact Factor: 4.5]
 10. Goel B, Tiwari AK, Pandey RK, Singh AP, Kumar S, Sinha A, Jain SK, Khattri A (2022) Therapeutic approaches for the treatment of head and neck squamous cell carcinoma—An update on clinical trials. *Transl Oncol.* **21**: 101426. [Impact Factor: 4.5]
 11. Yadav J, Das S, Singh S, Jyoti A, Srivastava VK, Sharma V, Kumar S, Kumar S, Kaushik S (2022) Deciphering the role of *Enterococcus faecalis* S-adenosyl homocysteine nucleosidase in quorum sensing mediated biofilm formation. *Curr Protein Pept Sci.* **23**: 211-225. [Impact Factor: 1.9]
 12. Kumar A, Parashar R, Kumar S, Faiq MA, Kumari C, Maheswari K, Narayan RK, Jha RK, Singh HN, Prasoon P, Pandey SN, Kant K (2022) Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19. *J Med Virol.* **94**: 1300-1314. [Impact Factor: 6.8]
 13. Kumar A, Asghar A, Raza K, Narayan RK, Jha RK, Satyam A, Kumar G, Dwivedi P, Sahni C, Kumari C, Kulandhasamy M, Motwani R, Kaur G, Krishna H, Sesham K, Pandey SN, Parashar R, Kant K, Kumar S (2021) Demographic characteristics of SARS-CoV-2 B.1.617.2 (Delta) variant infections in Indian population. <https://doi.org/10.1101/2021.09.23.21263948>
 14. Kumar A, Narayan RK, Prasoon P, Kumari C, Kaur G, Kumar S, Kulandhasamy M, Sesham K, Pareek V, Faiq MA, Pandey SN, Singh HN, Kant K, Shekhawat PS, Raza K,

- Kumar S** (2021) COVID-19 mechanisms in the human Body-what we know so far. *Front Immunol.* **12**: 693938 [Impact Factor: 5.7]
15. Rana S, Kaur KN, Kumar A, **Kumar S**, Singh H (2021) Criteria for the identification of suspect SARS-CoV-2 reinfection cases. *Curr Sci.* **121**: 1153-1155. [Impact Factor: 1.1]
 16. Kumar A, Narayan RK, Maheswari K, Prasoon P, Kumari C, **Kumar S**, Pareek V, Sesham K, Shekhawat PS, Kant K, Kumar S (2021) COVID-19 Pandemic: Insights into Molecular Mechanisms Leading to Sex-based Differences in Patient Outcomes. *Expert Rev Mol Med.* **23**: e7, 1–12. [Impact Factor: 4.5]
 17. Kumar A, **Kumar S**, Narayan RK, Kumari C, Pareek V, Prasoon P (2021) Expression of SARS-CoV-2 host-cell entry factors in immune system components of healthy individuals and its relevance for COVID-19 immunopathology. *Viral Immunology* **34**: 352-357. [Impact Factor: 1.5]
 18. Mittal A, Manjunath K, Ranjan RK, Kaushik S, **Kumar S**, Verma V (2020) COVID-19 Pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. *PLoS Pathogens* **16**: e1008762. [Impact Factor: 5.5]
 19. Cope N, Candelora C, Wong K, **Kumar S**, Nan H, Grasso M, et al. (2018) Mechanism of BRAF activation through biochemical characterization of the recombinant full-length protein. *Chembiochem* **19**: 1988-1997. [Impact Factor: 2.6]
 20. Das U, Howlett J, **Kumar S**, Parameswaran S, Sharma A, Dimmock JR, Sharma RK (2018) *N*-myristoyltransferase (NMT). In: Choi S. (Ed.), *Encyclopedia of Signaling Molecules*. 2nd ed. Springer-New York. **2**: 3522-3533. [Book Chapter, International; ISBN: 978-3-319-67198-7]
 21. Sharma RK, Das U, Parameswaran S, **Kumar S**, Dimmock JR (2017) Calpain activity and expression in human colonic tumors. In: Chakraborti S, Dhalla NS (Eds.) *Pathophysiological Aspects of Proteases*. Springer-New York. Pages: 161-170. [Book Chapter, International; ISBN: 978-981-10-6140-0]
 22. **Kumar S**, Das U, Dimmock JR, Sharma RK (2017) Role of Proteases in the regulation of *N*-myristoyltransferase. In: Chakraborti S, Dhalla NS (Eds.) *Proteases in Physiology and Pathology*. Springer-New York. Pages: 89-99. [Book Chapter, International; ISBN: 978-981-10-2512-9]
 23. **Kumar S**, Parameswaran S, Sharma RK (2015) Novel myristoylation of the sperm-specific hexokinase 1 isoform regulates its atypical localization. *Biol Open* **4**: 1679–1687. [Impact Factor: 1.8]
 24. **Kumar S**, Sharma RK (2015) N-terminal region of the catalytic domain of human *N*-myristoyltransferase 1 acts as an inhibitory module. *PLoS ONE* **10**: e0127661. [Impact Factor: 2.9]
 25. Sharma RK, **Kumar S**, Parameswaran S, Dimmock JR (2014) Regulation of *N*-myristoyltransferase by the calpain and caspase systems. *Indian J Biochem Biophys* **51**:506-511. [Impact Factor: 1.5]
 26. **Kumar S**, Sharma RK (2014) An improved method and cost effective strategy for soluble expression and purification of human *N*-myristoyltransferase 1 in *E. coli*. *Mol Cell Biochem* **392**:175-186. [Impact Factor: 3.5]
 27. Parameswaran S, **Kumar S**, Sharma RK (2013) Cardiomyocyte culture – an update on the *in*

in vitro cardiovascular model and future challenges. *Can J Physiol Pharm* **91**: 985-998. [Impact Factor: 2.1]

28. Parameswaran S, **Kumar S**, Sharma RK (2013) Role of calpains in calmodulin regulated systems. In: Chakraborti S, Dhalla NS (Eds.) *Proteases in Health and Disease*. Springer-New York. Pages: 33-48. [Book Chapter, International; ISBN: 978-1-4614-9232-0]
29. **Kumar S**, Selvakumar P, Sharma RK (2012) Phosphodiesterase 1. In: Choi S. (Ed.), *Encyclopedia of Signaling Molecules*. 1st ed. Springer-Verlag New York. **1**: 1381-1388. [Book Chapter, International; ISBN: 978-1-4419-0460-7]
30. **Kumar S**, Selvakumar P, Dimmock JR, Sharma RK (2012) N-myristoyltransferase (NMT). In: Choi S. (Ed.), *Encyclopedia of Signaling Molecules*. 1 ed. Springer-Verlag New York. **1**: 1245-1254. [Book Chapter, International; ISBN: 978-1-4419-0460-7]
31. Das U, **Kumar S**, Dimmock JR, Sharma RK (2012) Inhibition of protein N-myristoylation: A therapeutic protocol in developing anticancer agents. *Curr Cancer Drug Targets* **12**: 667-692. [Impact Factor: 2.3]
32. **Kumar S**, Singh B, Dimmock JR, Sharma RK (2011) N-myristoyltransferase in the leukocytic development processes. *Cell Tissue Res* **345**: 203-211. [Impact Factor: 3.2]
33. **Kumar S**, Dimmock JR, Sharma RK (2011) The potential use of N-myristoyltransferase as a biomarker in the early diagnosis of colon cancer. *Cancers* **3**: 1372-1382. [Impact Factor: 4.5]
34. Selvakumar P, **Kumar S**, Dimmock JR, Sharma RK (2011) NMT1 (N-myristoyltransferase 1). *Atlas Genet Cytogenet Oncol Haematol* **15**: 570-575.
35. Datta S, Kumar RS, Ayyadurai N, **Kumar S**, Sakthivel N (2004) Polysaccharides of *Pseudomonas* pathovar strains that infect pea, tomato, and soya bean. *Curr Microbiol* **49**: 35-41. [Impact Factor: 2.3]
36. Rajendra K, Prabha S, **Kumar S**, Thakur, IS (2010) Procurement of pentachlorophenol degrading bacteria from tannery effluent for their waste water treatment. In Recent Trends in Water Research: Hydrochemical and Hydrological Perspectives, IK International Publishing House Pvt Ltd, New Delhi. Pages: 173-182. [Book Chapter, National; ISBN: 978-9380026916]

H. Conference Presentations

1. Kumar A, Narayan RK, Kumari C, Pareek V, Prasoon P, **Kumar S** (2021) Nrp1 and furin as putative mediators of SARS-CoV-2 entry in human brain cells. Society for Neuroscience (SfN) Chicago, USA. 2021 #5672.
2. **Kumar S**, Candelora C, Cope N, Nan H, Wong K, Wang, Z (2017) Molecular Mechanisms of BRAF regulation: Looking beyond the kinase domain. The 10th Annual Frontiers in Chemistry and Biology Interface Symposium, University of Delaware, Delaware, USA. July 2017 Poster #49
3. **Kumar S**, Sharma RK (2016) Regulation of N-myristoyltransferase by Akt/PKB Mediated Phosphorylation. [Experimental Biology, EB2016, San Diego, USA]. *FASEB J* **30**: 835.9

4. **Kumar S**, Parameswaran S, Sharma RK (2015) The N-Terminal Atypical Region Regulates Non-Mitochondrial Localization of Novel Hexokinase Isoform". [Experimental Biology, EB2015, Boston, USA]. *FASEB J* **29**: 728.35
5. **Kumar S**, Parameswaran S, Sharma RK (2014) Dynamic Regulation of Hexokinase by Myristoylation in Absence of Specified Sequence Motifs. "Chemical Biophysics Symposium (CBP)", University of Toronto. May 2-4 **Abstract #P22**
6. **Kumar S**, Sharma RK (2012) Structural and functional characterization of N-terminus $\Delta 28$ of the shorter isoform of human N- myristoyltransferase 1. "3rd international conference on Stem Cells and Cancer (ICSCC-2012): Proliferation, Differentiation and Apoptosis". October 27-30 **Abstract #263**
7. **Kumar S**, Sharma RK. (2011) Role of chaperones in regulation of N-myristoyltransferase in cancer. "New Horizons in Cancer Research: Biology to Prevention to Therapy", American Association for Cancer Research (AACR). December 13-16. **Abstract #A-77**

I. Invited Talks

1. **Kumar S** (2023) **Pathogenesis mechanisms for long-term neuro-COVID. Invited Speaker** - 41st Annual Meeting of the Indian Academy of Neurosciences (IAN) and the International Conference on "Brain: Chemistry to Cognition", Jiwaji University, Gwalior, India. October 2023.
2. **Kumar S** (2022) **Protein Evolution: Impacts on Diseases Dynamics & Drug Resistance. Invited Speaker** - Department of Zoology, Science College, Patna University, Patna, India. May 2022.
3. **Kumar S** (2021) **Drug Discovery: Lessons learned and Challenges ahead for COVID-19. Invited Speaker** - in the national webinar on "Computer Aided Drug Design: A Loom for Drug Discovery" Department of Genetic Engineering, SRM Institute of Science & Technology, Chennai, India. March 2021.
4. **Kumar S** (2021) **Overcoming Drug Resistance in Cancers: What Lies Next for Therapy?** World Cancer Day, Organized by Union for International Cancer Control (UICC) Cancer Patients Aids Associations Mumbai, India. February 2021.
5. **Kumar S** (2020) **Directed Evolution of Enzymes and How to Enhance Their Properties. Speaker of Eminence** in the national workshop on "Microbial Diversity: Source of Novel Antimicrobial Therapeutics & Industrial Enzymes" AKS University, Satna, India. October 2020.
6. **Kumar S** (2020) **Protein Purification: From Industrial Enzymes to Cancer Therapy. Speaker of Eminence** in the national workshop on "Microbial Technology for Industries and Bioprocessing" AKS University, Satna, India. September 2020.
7. **Kumar S** (2019) **Biotechnological Applications in Development of Precision Medicine. Department of Biotechnology, College of Commerce, Arts & Science (NAAC-A Graded), Patna, India. March 2019.**
8. **Kumar S** (2018) **Understanding Drug Resistance and the Impact of Common Beliefs. Keynote Speaker**; Biotechnology. Bihar Science Conference, Patna, India. December 2018.
9. **Kumar S** (2018) **Science, Society and Common Beliefs. Amity University Patna, India. December 2018.**

10. **Kumar S** (2014) **Protein Myristoylation: An Ubiquitous Regulator for Membrane Targeting**. “*International Conference on Biotechnology and Bioinformatics (ICBB-2014)*”, Pune, India, February 2014.

J. Conference/Workshop’s Organized

1. **Organizer** International Conference on “**Advances in Biotechnology: Current Discoveries and Future Perspectives (ICAB-2023)**” held October 2023. *Amity Institute of Biotechnology, Amity University Maharashtra.*
2. **Convener** National Symposium on ‘**Rare Diseases: Perspectives & Challenges**’ held in the Rare Disease Month, February 2022. *Centre for Proteomics & Drug Discovery, Amity University Maharashtra.*